Anti-HER2 Antibody-drug Conjugate IBI354 clinical trials
Also written IBI354.
Its developmentBy Innovent Biologics, step by step3 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-HER2 Antibody-drug Conjugate IBI354 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-HER2 Antibody-drug Conjugate IBI354 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- IBI354
- 4
Studies by the year they started
4 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Innovent Biologics (Suzhou) Co. Ltd. (2) · Fudan University (1) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. (1)
Often tested with
Tested in the same studies.
Dalpiciclib (1) · Pyrotinib (1) · Trastuzumab rezetecan (1) · Adebrelimab (1) · Camrelizumab (1) · Tizetatug rezetecan (1) · Pertuzumab (1) · Trastuzumab (1)
Studies
Open first, then newest update. How each study uses Anti-HER2 Antibody-drug Conjugate IBI354 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as IBI354How we know
- IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast CancerRecruitingPhase 3Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.NCT07377643Written as IBI354How we know
- A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid TumorsRecruitingPhase 1/2Innovent Biologics (Suzhou) Co. Ltd.NCT05636215Written as IBI354How we know
- Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT06834672Written as IBI354How we know